Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Roland Leung"'
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 525-547 (2024)
Abstract Introduction The phase III randomized KEYNOTE-522 trial demonstrated that pembrolizumab in combination with chemotherapy as neoadjuvant treatment followed by adjuvant pembrolizumab (pembrolizumab + chemotherapy) provided significant improvem
Externí odkaz:
https://doaj.org/article/499f6d95549e4000968fd31438b2f8fc
Publikováno v:
Hepatology Communications. 7
Autor:
Malcolm A.S. Moore, Robert G. Maki, Michael LaQuaglia, Mark Edgar, Roland Leung, Yildirim Dogan, Anna Franceschino, Emil Lou, Andre L. Moreira, John Healey, Robert J. Downey, Alexei Morozov
Supplementary Figure S1 and Supplementary Tables S1-S2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07aa4081b6f872613f3817d491d7a302
https://doi.org/10.1158/1078-0432.22442586.v1
https://doi.org/10.1158/1078-0432.22442586.v1
Autor:
Malcolm A.S. Moore, Robert G. Maki, Michael LaQuaglia, Mark Edgar, Roland Leung, Yildirim Dogan, Anna Franceschino, Emil Lou, Andre L. Moreira, John Healey, Robert J. Downey, Alexei Morozov
Purpose: Recent evidence suggests that at least some sarcomas arise through aberrant differentiation of mesenchymal stromal cells (MSCs), but MSCs have never been isolated directly from human sarcoma specimens.Experimental Design: We examined human s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6c6370b931f0e665d5402da3ecff280
https://doi.org/10.1158/1078-0432.c.6519276
https://doi.org/10.1158/1078-0432.c.6519276
Autor:
Chi Tao Ng, Angela M Liu, Thomas Yau, Tan To Cheung, Paul N. M. Cheng, Gerry Gin Wai Kwok, Joanne Chiu, Roland Leung
Publikováno v:
Investigational New Drugs. 40:314-321
Introduction. We investigated the safety and efficacy of a pegylated arginase (PEG-BCT-100) in combination with chemotherapy (oxaliplatin and capecitabine) [PACOX] in advanced HCC patients. Methods. This was a single centre phase 1 trial to assess th
Autor:
Joanne Chiu, Polly S. Y. Cheung, Josephine Tsang, Roland Leung, Dacita Suen, Thomas Yau, Gerry Kwok, Ava Kwong, Bryan Cho Wing Li, T. T. Wong
Publikováno v:
Advances in Therapy. 38:5752-5762
Concurrent anthracycline and taxane is an effective and efficient way to deliver neoadjuvant chemotherapy for HER2-negative breast cancers. Data on efficacy and tolerance to 6 cycles of concurrent docetaxel, epirubicin, and cyclophosphamide (TEC) is
Autor:
Thomas Yau, Vikki Tang, Wong Hoi She, Ka Wing Ma, Josephine Tsang, Gerry Gin Wai Kwok, Tan To Cheung, Albert C. Y. Chan, Bryan Cho Wing Li, Kit Shing, Joanne Chiu, Chung Mau Lo, Roland Leung
Publikováno v:
Advances in Therapy. 38:3900-3910
Treatment of hepatocellular carcinoma (HCC) recurrences following liver transplant (LT) is challenging. Most clinical trials of systemic therapies for advanced HCC excluded patients with any history of organ transplant. We aimed to assess the outcome
Autor:
Tan To Cheung, Thomas Yau, Paul N. M. Cheng, Chi Tao Ng, Gin Wai Kwok, Angela M Liu, Joanne Chiu, Roland Leung
Introduction: We investigated the safety and efficacy of PEG-BCT-100 in combination with oxaliplatin and capecitabine (PACOX) in advanced HCC patients.Methods: This was a single centre phase 1 trial to assess the safety and tolerability of PACOX. All
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::456fac107207d0fe6babe223f6fad83e
https://doi.org/10.21203/rs.3.rs-717203/v1
https://doi.org/10.21203/rs.3.rs-717203/v1
Autor:
Ching-Hung Lin, Seock-Ah Im, Huiping Li, Takayuki Ueno, Kyung-Hun Lee, Yoon Sim Yap, Yoichi Naito, Winnie Yeo, Yen-Shen Lu, Yeon Hee Park, Roland Leung, Qiang Liu
Publikováno v:
Breast Cancer Research and Treatment. 177:549-559
Breast cancer in young Asian women has distinctive clinicopathological characteristics; hence, we question the universal generalizability of treatment recommendations based on data from predominantly non-Asian postmenopausal women. The Asian Breast C
Publikováno v:
Postgraduate medical journal. 98(1163)
Background Subcutaneous (SC) trastuzumab is similar to intravenous trastuzumab in terms of pharmacokinetics, efficacy and tolerability. The use of dual anti-HER2 agents trastuzumab and pertuzumab has become the new standard for node-positive HER2-pos